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Abstract
Background: Tocopherols have biphasic, proangiogenic and antiangiogenic therapeutic effects. The objective of
this clinical trial was to clarify tocopherol’s placental angiogenic potential in late pregnant ewes following oral
supplementation.
Methods: Eighteen pregnant ewes during late gestation were selected for this study. Ewes were given oral
supplementation of 500 mg of alpha-tocopherol (aT; N = 6) or 1000 mg of gamma-tocopherol (gT; N = 7) or
placebo (CON; N = 5) once daily from 107 to 137 days post breeding. Serum was obtained at weekly intervals and
tissue samples were obtained at the end of supplementation to: 1) evaluate tocopherol concentrations in serum,
uterus and placentome; 2) evaluate relative mRNA expressions of Vascular Endothelial Growth Factor (VEGF),
Placental Growth Factor (PlGF), endothelial Nitric Oxide Synthase (eNOS) and Hypoxia Inducible Factors (HIF) in
uterus, caruncle and cotyledon; 3) analyze the morphometry of the placental vascular network.
Results: Supplementation of aT or gT resulted in increased concentrations in serum, placentome and uterus
compared to control (P < 0.05). In aT group, mRNA expressions of PlGF, eNOS and HIF-1a in cotyledon were
greater than the CON group. In gT group, mRNA expressions of VEGF, eNOS, HIF-1 alpha and HIF-2 alpha in
caruncle and uterus, and HIF-1a in cotyledon, were greater than the CON group. Morphometry analysis revealed
increased angiogenesis in the supplemented groups.
Conclusion: Daily oral supplementation of aT or gT increased angiogenesis in the placental vascular network in
pregnant ewes during late gestation. Increase in placental angiogenesis may provide nutrients required for the
development and growth of fetus during late pregnancy.
Background
Angiogenesis is the process of development of new
blood vessels from an existing vascular network [1].
Hypoxia constitutes a basic regulatory mechanism in
vascular development during embryonic and fetal
growth in utero [2]. In endothelial cells, hypoxic condi-
tions drive the transcription of multiple genes which
control vascular function, expansion and remodeling.
Although tissue hypoxia is the main driving force for
angiogenesis, a growing body of evidence has demon-
strated that oxidative stress can also be a potent trigger
for the development of new vessels [3-6].
Two families of radicals, reactive oxygen species (ROS)
and reactive nitrogen species (RNS) are very crucial to
growth, differentiation, apoptosis, and aging. The transi-
tion from growth to degeneration of cells is finely tuned
by the relative concentration of oxidants. For instance,
in ambient conditions, H2O2 in nano-micromolar con-
centrations are necessary for angiogenesis [7], while its
excessive accumulation at levels more than 150-200 μM
prompts endothelial damage [8]. An imbalance of free
radicals attacks and alters cell constituents, resulting in
lipid peroxidation, protein peroxidation, oxidative inacti-
vation, mutation of DNA, and destruction of vitamins
and other functions that protect cell components [9].
Excessive accumulation of free radicals affects placental
development and function, and may subsequently
impact both the fetus and dam [10-13]. The dietary
antioxidants are important in attenuating the oxidative
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damage produced by radicals [13,14]. Tocopherols are
micronutrients which act as free radical scavengers. The
major tocopherols found in mammalian tissue are
alpha-tocopherol (aT) and gamma-tocopherol (gT). Stu-
dies on tocopherol in humans have shown that aT con-
stitutes 80 to 90% of vitamin E in plasma, which is due
to the preferential incorporation of aT into very low-
density lipoprotein via tocopherol-binding protein, and a
rapid catabolism of gT within the liver [14]. Conse-
quently, aT has received the most attention and is the
primary form of vitamin E in supplements. However a
recent work has suggested that under specific circum-
stances gT might scavenge reactive species more effec-
tively than aT thereby, being more beneficial [15,16].
Gamma tocopherol affords higher protection against
lipid peroxidation as compared to aT [17]. It has been
demonstrated that high levels of aT intake can decrease
gT [17]. Also gT has synergistic effect with other toco-
pherols and suggested as most promising agent to use.
Hence we decided to use both tocopherols in this study.
Human and animal studies have demonstrated that
chronic supplementations with tocopherols have bipha-
sic, proangiogenic and antiangiogenic therapeutic effects
[18-22]. A recent study also concluded that tocoretinols
not tocopherols suppressed Vascular Endothelial Growth
Factor (VEGF) induced angiogenesis [23].
Optimal placental development is critical for fetal
development and growth. Normal fetal growth is geneti-
cally pre-programmed and regulated by fetal, placental,
maternal and environmental factors. A range of patho-
physiological factors including maternal stress due to
poor nutrition, hyperthermia or metabolic diseases such
as pregnancy toxemia and eclampsia may affect impor-
tant metabolic, transport and hemodynamic functions of
placentas. This may lead to fetal stress due to poor sup-
ply of nutrition and thus impairment in fetal growth. A
recent study demonstrated that glucocorticoid induced
restriction of fetal and placental growth is mediated
through reduced placental expression of VEGF and
associated reduction in placental vascualrization during
late pregnancy [24]. Supplementation of antioxidants
may negate oxidative stress, promote angiogenesis and
increase nutrient supply to the fetus. The differential
expression of VEGF and placental growth factors (PlGF)
throughout gestation indicates that they both play essen-
tial roles in placental angiogenesis. Hypoxia inducible
factor (HIF)-1a or HIF-2a combine with HIF-1b to
form the functional basic helix-loop-helix transcription
factor HIF-1 to stimulate transcription of the VEGF
gene via interaction with the hypoxia response element
(HRE) [25]. Several genes encoding growth factors and
tyrosine kinase receptors essential for endothelial cell
growth and function such as erythropoietin (EPO),
VEGF, endothelial Nitric Oxide Synthase (eNOS) and
Flk-1 were shown to contain HIF-binding sites in their
promoter/enhancer sequences.
We hypothesize that oral supplementation of toco-
pherols during late gestation in ewes will increase toco-
pherol levels in the circulation, resulting in increased
concentrations in the uterus and placenta and thereby
increasing the expression of angiogenic genes and exert-
ing an angiogenic effect. The objectives of the study
were to: 1) compare aT and gT concentrations in
serum, uterine and placentomal tissues among supple-
mented and CON groups; 2) compare angiogenic gene
(VEGF, PlGF, eNOS, and HIFs) expressions in the
uterus, caruncle and cotyledon among supplemented
and CON groups; and 3) compare angiogenic morpho-
metric parameters of the uteroplacental vascular net-
work of late pregnant ewes supplemented with aT, gT,
or placebo.
Methods
Eighteen pregnant ewes (2 to 6 years of age and weigh-
ing approximately 68 kg; impregnated by different sires
by natural service), with similar breeding dates were
selected for the current study and were mainatined
under normal pasture conditions. One week prior to the
trial, the selected ewes were moved to the research facil-
ity and were penned by treatment groups. The ewes had
access to 35 sq ft/ewe paddock lots. In addtion they
were fed 250 g of concentrate/ewe/day and free choice
hay. The composition of hay is given in Additional file
1, Table S1. This study was approved by Virginia Tech
institutional animal care and use committee (IACUC;
04-068-CVM). Tissue Use Protocol was approved by
IACUC at Washington State University (ASAF #03922-
001).
The ewes were randomly assigned to three groups: 1)
aT group (n = 6) - received 500 mg of aT (Nature’s
Bounty, Bohemia, NY 11716), 2) gT group (n = 7) -
received 1000 mg of gT (Kemin Industries Inc., Des
Moines, Iowa 50317), 3) Control (CON) group (n = 5) -
received a placebo. The average tocopherols concentra-
tions in the supplement is given in Additional file 2,
Table S2. Animals were supplemented orally, once daily,
from approximately 100 to 137 days post breeding (dpb)
(Figure 1). Blood samples were collected one week prior
to onset of supplementation and then weekly until the
end of the supplementation period [94 dpb (presupple-
ment level), 107 dpb, 114 dpb, 121 dpb, 128 dpb, 136 ±
1 dpb] for serum aT and gT evaluation (Figure 1). At
the end of the supplementation period (136 ± 1), all
ewes were euthanized and tissue samples were collected
from the gravid uterus and placentomes to evaluate aT
and gT concentrations. Tissue samples were snap frozen
and stored at -70°C until analysis. Caruncle, cotyledon
and intercaruncular uterus samples were also collected
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and stored in RNAlater (Qiagen Inc., Valencia, CA
91355) and frozen at -70°C to evaluate mRNA expres-
sion. Cotyledones were separated from caruncles by
applying strong pressure. Placentomal and uterine tis-
sues were collected close to the umbilical cord for
consistency.
Serum tocopherol estimation
The High Performance Liquid Chromatography (HPLC)
method described by Panfili et al (2003) was employed
for the quantification of tocopherols [26]. For each sam-
ple, dose-dependent (10, 50, 100, 500 and 1000 mg/L)
tocopherols (Sigma-Aldrich, St. Louis, MO 63103) posi-
tive control were prepared. In a glass tube, 1 mL of
serum sample and 20 μL of aT acetate (1000 mg/L) in
ethanol (internal standard to estimate yield of extrac-
tion) was added and vortexed. To this 1 ml of ethanol
containing 0.01% of butylated hydroxytoluene (BHT)
was added. The tocopherols were extracted 3 times with
1 ml of cyclohexane containing 0.01% BHT. After eva-
poration of the pooled cyclohexane fractions under a
stream of nitrogen, the residues were reconstituted in
200 μL of cyclohexane. The samples were filtered
through a Pall Gellman Acrodisc® (0.2 μm/13 mm) into
a HPLC vial and subjected to a HPLC analysis to quan-
tify the tocopherol’s concentration.
Uterine and placentomal tissue tocopherol estimation
The HPLC method described by Katsanidis and Addis
(1999) was employed for quantification of tocopherol
concentrations in uterus and placentome samples [27].
Each uterine and placentomal tissue sample was homo-
genized separately in water (1:2) containing ascorbic
acid (62.5 g of ascorbic acid in 250 mL of double dis-
tilled water) to protect tocopherol from air oxidation
during saponification process [27]. The tissue homoge-
nates were aliquoted and frozen and stored at -70°C
until analysis. One point five grams of uterus or placen-
tal homogenate was placed in a screw cap tube and
0.125 g of ascorbic acid and 3.5 mL of the saponification
solution [55% ethanol in distilled water and 11% KOH
(w/v)] were added to the tissue. The tube with sample
was heated to 80°C for 15 min. After saponification, the
tubes were cooled under tap water for 1 min, and then
1 mL of distilled water was added. The solutions were
extracted 3 times with 1 mL of cyclohexane containing
0.01% of BHT. The 3 extracts were combined and the
solvent was evaporated under reduced pressure by a
rotovap. The residue was reconstituted in 500 mL of
ethanol containing 0.01% BHT.
An Agilent Technologies 1100 series liquid chromato-
graphy system (Agilent Technologies Inc. Santa Clara,
CA 95051, USA) was used to perform HPLC analysis to
quantify tocopherols in supplement, serum, and tissue
samples. The analysis was conducted in normal phase,
with a HPLC column Agilent Technologies Zorbax Rx-
Si 150 × 4.6 mm, 5 μ with an elution solvent constituted
of hexane-isopropanol (99.7:0.3) with a flow rate of
1 mL/min and an injection volume of 10 μL. The toco-
pherols were analyzed by fluorescence with an excitation
wavelength of 295 nm and emission wavelength of
330 nm.
Real Time Polymerase Chain Reaction
Total RNA was extracted with RNeasy Mini Kit (QIA-
GEN Inc. Valencia, CA, USA) according to the manu-
facturer’s protocol from uterine and placental tissues.
Total RNA (1 μg) was reverse transcribed into cDNA
with a SuperScript II reverse transcriptase (Invitrogen,
Carlsbad, CA 92008, USA) using random hexamers as a
primer. Primers for the genes examined are listed in
Table 1. To ensure the amplification of a single ampli-
con of the expected size, the product was viewed on an
ethidium bromide stained electrophoresis gel. The RT-
PCR analyses for VEGF, PlGF, eNOS, HIFs and 18 S
rRNA were performed using the ABI 7300 Sequence
Detection System instrument and software (PE Applied
Biosystems Inc., Foster City, CA, USA). To compare
mRNA expression levels among samples, mRNA for
each gene of interest was normalized to the expression
of a housekeeping gene, 18 s RNA, and differences in
gene expression were calculated as a fold change to the
mean of the vehicle group using the 2-ΔΔCt method
[28,29].
Morphometry analysis
The placentome samples collected for histological eva-
luation were fixed in 10% neutral buffered formalin, sec-
tioned at 5 microns, and stained with hematoxylin and
eosin. They were evaluated on a Nikon E400 Eclipse
microscope, and photomicrographs (100×) were taken
with a Nikon camera with a 3 chip. Images were pro-
cessed with Nikon Act 1 software. Image processing and
morphometry analysis were performed using ImageJ
1.42 q (NIH, USA) to evaluate the fractal dimension and
Figure 1 Schematic representation of treatment regimen and
sample collection. dpb - days post breeding.
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lacunarity [30,31]. The main processing steps applied to
the images are shown in Figure 2. Briefly, after down-
loading the original image in the software, they were
converted to 8 bit black and white images, and thresh-
olding was performed by selecting mean value as thresh-
old value. The images were made binary and were
skeletonized.
Fractal analysis is a contemporary method of applying
nontraditional mathematics to patterns that defy under-
standing with traditional Euclidean concepts. Fractal
analysis measures complexity using the fractal dimen-
sion. A fractal dimension is, in essence, a scaling rule
comparing how a pattern’s detail changes with the scale
at which it is considered. The fractal dimension is a
Table 1 Primer sequences for Vascular Endothelial Growth Factor, Placental Growth factor, endothelial Nitric oxide
Synthase and Hypoxia Inducible Factors
Gene Primer Sequence 5’ to 3’ GenBank accession number
VEGF Forward TGTAATGACGAAAGTCTGGAG AF071015
Reverse TCACCGCCTCGGCTTGTCACA
PlGF Forward TGCCGGTCATGAGGCTGT NM_002632*
Reverse GCAGTCACTGAAGAGTGTGAC
eNOS Forward TGGGCCGCATCCAGTG NM_001129901
Reverse GAACATCTCCTGTGCTGAGCTG
HIF-1a Forward TCAGCTATTTGCTGTGAGG EU340260
Reverse TTCACAAATCAGCACCAAGC
HIF-1b Forward AGA TGC AGG AAT GGA CTT GG EU340261
Reverse CCT GGC CTT TTA ACT TCA CG
HIF-2a Forward AAGTCAGCCACCTGGAAGG EU340264
Reverse TCACACACATCATGCACTGG
HIF-2b Forward AGGATGAGGTGTGGAAATGC EU340265
Reverse CCTCAGAGTGGCAGAACTCC
*Homology to human
Figure 2 Steps involved in image processing of histological sections of placentome using ImageJ 1.42 q. a. histological image of
placental vascular network (Bar = 50 μm; 100× magnification); b. 8 bit image; c. Image smoothened; d. Image with edges; e. Binary conversion; f.
Skeletonization.
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valuable parameter to describe the complexity. FarcLac
2.5 release 1b5 m (NIH, USA) was used to perform frac-
tal dimension. The FracLac scan images using a shifting
grid algorithm that can do multiple scans from different
locations on each image. The fractal dimension of the
binary skeleton was estimated using the box counting
method at multiple origins. The basic procedure is to
systematically lay a series of grids of decreasing calibre
(the boxes) over an image and record data (the count-
ing) for each successive calibre. To minimize grid loca-
tion effects, the algorithm started from number of
locations, generating a set of variables for fractal dimen-
sion. The average value over all locations was consid-
ered as the final estimate of fractal dimension. During
the same analytical process ‘Lacunarity” was also calcu-
lated. This parameter is a measure of homogeneity of
structure or the degree of structural variance within an
object. It was estimated as the average of the coefficient
of variation for pixel density over all grid sizes and loca-
tions. The field demarked as a square in Figure 3 is one
location. A total of 30 locations were evaluated for each
sample.
Statistical analyses
The MIXED procedure of the SAS System (SAS version
9.12, SAS Institute Inc., Cary, NC 27513) was used to
perform a repeated measures analysis of covariance to
test for effects of treatments (aT, gT and CON), days
post breeding [94 dpb (pre-supplement level), 107 dpb,
114 dpb, 121 dpb, 128 dpb), 136 ± 1 dpb] and their
interactions on the serum concentration of tocopherols.
Covariation of repeated measurements was modeled as
compound symmetric and model adequacy was assessed
using plots of standardized residuals. The differences in
the serum tocopherol concentrations between pre-sup-
plement stage and post supplement stages of gestation
were tested by creating contrast statements. Analysis of
variance was used to determine the within treatment
between days post breeding differences and within days
post breeding between treatment differences. Since the
data were not normally distributed, a non-parametric
procedure was used to perform the Kruskal-Wallis
method test to compare the median tocopherol concen-
trations in serum, placenta and uterus among the treat-
ment groups (Table 2). For responses with significant
differences, pair-wise comparisons were performed using
Minitab 12.1 (Minitab Inc., State College, PA, USA).
The RT-PCR data were subjected to ANOVA using 2-
ΔΔCt values to ascertain statistical significance of any dif-
ferences in VEGF, PlGF, eNOS and HIFs expression in
placebo vs. tocopherol-treated groups [29]. The differ-
ences in fractal dimension and lacunarity among treat-
ment groups were tested by non-parameteric Kruskal-
Wallis method. There were 3 ewes (2 in CON and 1 in
Figure 3 Morphometric analysis of placental vascular network
of late pregnant ewes supplemented with alpha tocopherol,
gamma tocopherol or placebo. a. Morphometric parameter of
placental network of ewe supplemented with g tocopherol. Field
demarked as red-square had Fractal dimension 1.6204 and
lacunarity 0.4967. A total of 30 fields were evaluated for each
sample; b. Morphometric parameter of placental network of ewe
supplemented with a tocopherol. Field demarked as red-square had
Fractal dimension 1.7030 and lacunarity 0.5884. A total of 30 fields
were evaluated for each sample. c. Morphometric parameter of
placental network of ewe treated with placebo. Field demarked as
red-square had Fractal dimension 1.6263 and lacunarity 0.6033. A
total of 30 locations were evaluated for each sample.
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aT) that had twins. The the results did not change after
inclusion, exclusion averaging the the values from twins;
however excluded from the analysis.
Results
Serum tocopherol concentrations
Serum tocopherol concentrations were significantly dif-
ferent between treatment groups (P < 0.0001) and days
post breeding (P < 0.0001; Additional file 3, Table S3).
Significant treatment × days post breeding interaction
was observed (P < 0.0001; Additional File 3, Table S3).
The pre-supplementation serum levels of aT compared
to post-supplemental stages of gestation were different
between aT and gT groups (P < 0.0001; Additional file
4, Table S4), and between aT and CON groups (P <
0.0001; Additional file 4, Table S4) and not between
gT and CON groups (P > 0.05; Additional file 4, Table
S4). The pre-supplementation gT serum concentrations
compared to other stages of gestation were different
between gT and aT groups (P < 0.0001; Additional
file 4, Table S4), and between gT and CON groups
(P < 0.0001; Additional file 4, Table S4) and not
between aT and CON groups (P > 0.05 Additional file
4, Table S4).
Pair-wise comparisons of the median (25th, 75th per-
centile) serum aT concentrations (excluding pre-supple-
mentation level) were significantly higher for ewes in aT
group compared to ewes in gT and CON groups during
the trial period for the respective stages (P < 0.001; Fig-
ure 4a and additional file 4, Table S4). Pair-wise com-
parison of median tocopherol levels between stages
within treatment groups was different for the aT group
(P < 0.05) but not in gT and CON groups (P > 0.05).
Similarly, pair-wise comparisons of the median (25th,
75th percentile) serum gT concentrations (excluding
pre-supplementation level) were significantly higher for
ewes in the gT group compared to ewes in aT
and CON groups during the trial period for the respec-
tive stages (Figure 4b and additional file 4, Table S4).
Pair-wise comparison of median tocopherol levels
between stages within treatment groups was different
for the gT group (P < 0.05) but not in aT and CON
groups (P > 0.1).
Uterine and placental tocopherol concentrations
The median aT tocopherol concentration in placen-
tome and uterus was greater in ewes supplemented
with aT compared to ewes in gT and CON groups
(P < 0.05; Table 2). The median gT concentrations in
placentome and uterus were greater in ewes supple-
mented with gT compared to ewes in the aT and CON
groups (P < 0.05; Table 2). The median gT in the
uterus of CON ewes was greater than aT supplemen-
ted ewes (P < 0.05; Table 2).
Vascular Endothelial Growth Factor, Placental Growth
Factor, endothelial Nitrous Oxide Synthase and Hypoxia
Inducible Factors expression
Figure 5a shows expression of VEGF, PlGF and eNOS in
placenta and uterus in tocopherol supplemented groups
relative to CON, where control is 1. In cotyledon, the
PlGF and eNOS expression in ewes supplemented with
aT was significantly higher compared to the CON
group. The VEGF expression was not different between
aT and the CON groups. The VEGF, PlGF and eNOS
expressions in ewes supplemented with gT were not dif-
ferent from the CON group. In caruncle and uterus, the
VEGF and eNOS expressions in ewes supplemented
with gT were significantly higher compared to the CON
group. The PlGF expression was not different between
gT and the CON groups. The VEGF, PlGF and eNOS
expressions in ewes supplemented with aT were not dif-
ferent from the CON group.
The hypoxia inducible factors gene expression in toco-
pherol supplemented ewes relative to CON (1.0 fold) are
given in Figure 5b. Ewes that received aT showed an
increase in HIF-1a mRNA expression in cotyledon com-
pared to control (P < 0.05). In gT supplemented ewes,
the mRNA expressions of HIF-1a in cotyledon, and
HIF-1a and HIF-2 a in caruncle and uterus were higher
compared to controls (P < 0.05). There was no HIF-1b
expression in cotyledon, caruncle and uterus.
Morphometry analysis
The results showed that aT or gT supplemented ewes
had increased fractal dimension and decreased lacunar-
ity in their placental vascular network compared to
CON ewes (Figure 6; P < 0.05).
Discussion
The goal of this study was to investigate the differ-
ences in angiogenic potential of alpha- and gamma-
tocopherol. We evaluated biweekly serum, and uterine
Table 2 Median (25th and 75th percentile) tissue
concentrations of alpha- and gamma-tocopherols
between the treatment groups in ewes (N = 18)
Concentrations
Tissue Treatment Groups aT (mg/kg) gT (μg/kg)
Placenta aT 9.19 (6.77, 12.1)a 45.5 (10.0, 83.3)a
gT 2.74 (2.26, 6.22)b 607 (477, 1057)b
Control 2.88 (1.85, 4.16)b 92.4 (57.6, 153.0)a
Uterus aT 5.23 (4.38, 6.50)a 0 (0, 189.3)a
gT 3.28 (2.34, 3.54)b 737.7 (607.1, 979.6)b
Control 2.34 (1.91, 3.87)b 156.5 (110.3, 237.1)c
abcdifferent superscripts between treatment groups within tissue are significantly
different (P < 0.05); aT- alpha tocopherol; gT-gamma tocopherol; CON - Control
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and placental concentrations of tocopherols, angiogen-
esis gene (VEGF, PlGF, eNOS and HIFs) mRNA
expressions, and morphometry of placental vascular
network following daily oral supplementation in late
pregnant ewes. The findings of this study indicated
that oral supplementation of tocopherols to pregnant
ewes during late gestation increased their serum con-
centrations; increased their concentrations in uterine
and placentomal tissue; alpha tocopherol increased
mRNA expression of PlGF, eNOS and HIF-1a in coty-
ledon compared to placebo; gamma tocopherol
increased VEGF and eNOS mRNA expressions in car-
uncle and uterus, and HIF-1a in cotyledon, HIF-1a
and HIF-2 a in caruncle and uterus compared to pla-
cebo; morphometry analysis of angiogenic parameters
favored increased angiogenesis.
Figure 4 Serum tocopherol concentrations in late pregnant ewes supplemented with alpha tocopherol, gamma tocopherol or
placebo. a. Serum alpha tocopherol concentrations (mg/kg) during late pregnancy in supplemented ewes. Line graphs represent median
(25th,75th percentile); *- aT group significantly different from gT and CON group (P < 0.001); ab - Median values with different superscripts were
significantly different between days post breeding within aT group (P < 0.05); No differences between days post breeding were observed for gT
and CON groups; Bar - 25th and 75th percentile; dpb - days post breeding; aT - alpha tocoperhol; gT - gamma tocopherol; CON - placebo; b.
Serum gamma tocopherol concentration (μg/kg) during late pregnancy in supplemented ewes. Line graphs represent median (25th,75th
percentile); *- gT group significantly different from aT and CON group (P < 0.001); Median values with different letters were significantly different
between days post breeding within gT group (P < 0.05); No differences between days post breeding were observed for gT and CON groups;
Bar - 25th and 75th percentile; dpb - days post breeding; aT - alpha tocoperhol; gT - gamma tocopherol; CON - placebo.
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In this study, the serum and tissue level of aT (mg/kg)
was higher than gT (μg/kg) even with increased gT daily
dose. Gamma-tocopherol is initially absorbed in the same
manner as alpha-tocopherol following administration,
however, only small amounts of gamma-tocopherol are
detectable in blood and tissue [32]. The bioavailability of
aT is 5 to 10 times more than gT, could explain the rea-
son for lower serum and tissue gT [33,34]. Other factors
that could be responsible include high fat intake [35],
oxidative stress [36,37], dose and half-life [38], species
and cell type in question, and the chemical vitamer. The
d2-gamma-tocopherol half-life was 13 ± 4 h compared
with 57 ± 19 h for d6-alpha-tocopherol [38]. Considering
the half-life, the daily oral supplementation and biweekly
serum sample collection in this study occurred in the
mornings, between 0800 and 0900 h, and could also be
the possible explanation for the lower gamma tocopherol
levels in the serum. Also, it has been demonstrated that
aT transfer protein is present in early and late term pla-
centa in other species [39]. Hence it is possiblethat aT
was better able to transfer across to the cotyledon and
thereby increased tissue aT concentration.
Figure 5 Relative mRNA of target genes expressed in uterus and placenta of late pregnant ewes following oral supplementation of
alpha tocopherol, gamma tocopherol or placebo. a. Vascular endothelial growth factor, endothelial nitric oxide synthase, and placental
growth factor mRNA expression in placenta and uterus following alpha or gamma tocopherol oral supplementation (× expression relative to
control = 1; * P < 0.05); b. Hypoxia inducible factors (HIF-1a, HIF-2a, HIF-2b) expression in placenta and uterus following alpha or gamma
tocopherol oral supplementation (× expression relative to control = 1; * P < 0.05).
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Tocopherols exhibit complex biological effects reflect-
ing their diverse nutritional, antioxidant and signaling
properties [26]. The biologically active range of toco-
pherols is relatively narrow (~3-4-fold variation).
Because of this relatively narrow “window of efficacy,”
benefits from tocopherols might require continuous
consumption to be effective. Once ingested, orally admi-
nistered vitamin E plateaus in the plasma by 24 h but
does not fully distribute to all biological compartments
until at least ~1 week after ingestion [27]. It is consis-
tent in this study that the serum concentrations of both
aT and gT spiked during the first week and maintained
at increased levels during rest of the study.
Several factors including VEGF, PlGF, basic Fibroblast
Growth Factor (bFGF), epidermal growth factor, eNOS
and angiopoietins 1 and 2 have been recognized as
important regulators of placental development [2,40,41].
In the present study, alpha tocopherol increased mRNA
expression of PlGF in cotyledon compared to placebo,
and gamma tocopherol increased VEGF in caruncle and
uterus. In ewes, maternal placental vascularization is
dependent upon VEGF and angiopoietins expression. In
contrast, fetal placental vascularization depends on
numerous angiogenic factors [42,43]. It has been
demonstrated that both VEGF and PlGF driven angio-
genesis acts via an eNOS activated, nitric oxide
mediated pathway [44]. In this study, aT increased the
eNOS in cotyledon and gT increased the eNOS in car-
uncle and uterus. In pioneering studies, Cooney et al
[14,45] showed that tocopherol reduces nitrogen dioxide
to the less harmful nitric oxide. Because endothelium
derived nitric oxide is a key regulator of vascular home-
ostasis, up-regulation of endothelial nitric oxide synthase
and nitric oxide formation by tocopherol could be
important in promoting angiogenesis [46].
In this study aT, increased mRNA expression of HIF-
1a in cotyledon compared to placebo. The gT increased
mRNA expressions of HIF-1a in cotyledon, and HIF-1a
and HIF-2 a in caruncle and uterus compared to pla-
cebo. Hypoxia-inducible factor is the main regulator of
the cellular response to low oxygen levels in mammalian
species, playing a key role in regulating many physiolo-
gical functions. The 2 principal HIF-a subunits, HIF-1a,
which is ubiquitously expressed and HIF-2a, which
shows a spatially restricted expression, both play impor-
tant roles in vascular development and endothelial func-
tion [47-49]. Hypoxia inducible factor-1a or HIF-2a
combine with HIF-1b to form the functional basic helix-
loop-helix transcription factor HIF-1 to stimulate tran-
scription of the VEGF gene via interaction with the
hypoxia response element (HRE) [25]. This occurs
under hypoxic conditions, but is down regulated under
normoxic conditions due to targeted proteolysis of HIF-
1a and HIF-2a, mediated by the von Hippel-Lindau
tumor suppressor gene product (pVHL). Additionally,
VEGF is regulated post-transcriptionally through stabili-
zation of its mRNA by interaction with heterogeneous
nuclear ribonuceloprotein L (hnRNP L). The basic
helix-loop-helix transcription factor HIF-2a is also cap-
able of heterodimerizing with HIF-1a to form functional
HIF-1. Several genes encoding growth factors and tyro-
sine kinase receptors essential for endothelial cell
growth and function such as EPO, VEGF, eNOS and
Flk-1 were shown to contain HIF-binding sites in their
promoter/enhancer sequences.
Although placental and fetal growth and development
are driven by the program encoded in its genome, the
genetic regulation is influenced by the intra-uterine
environment in which the fetus grows. The size and
nutrient transfer capacity of the placenta plays a central
role in determining the prenatal growth trajectory of the
fetus. Angiogenesis is the process of formation of new
vessels from preexisting vessels. Although tissue hypoxia
is the main drive for angiogenesis, a growing body of
evidence has demonstrated that oxidative stress can also
be a potent trigger for the development of new vessels.
Hence it seems reasonable that the presence of no or
high oxidative stress may result in formation of new ves-
sels. Angiogenic sprouting is controlled by the balance
between pro-angiogenic signals (VEGF) and factors that
promote quiescence (pericyte) or VEGF inhibitors [50].
In conditions that favor angiogenesis, some endothelial
cells can sprout, whereas others fail to respond. In the
present study, morphometric analysis revealed ewes sup-
plemented with alpha- or gamma-tocopherol had
increased fractal dimension and decreased lacunarity
compared to placebo treated ewes indicated increased
angiogenesis in utero-placental vascular network. It
should be noted that even though not significant
reduced mRNA expressions for VEGF, PlGF and eNOS
in uterus and placenta were observed in this study.
Figure 6 Fractal dimension and lacunarity of placental vascular
network of late pregnant ewes supplemented with alpha
tocopherol, gamma tocopherol or placebo. Bar graph represents
expression of fractal dimension and lacunarity of treated groups.
Groups with different letters were significant (P < 0.05).
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Conclusions
This study evaluated cellular responses to supplementa-
tion in order to understand the mechanisms behind the
biological effects of tocopherols on placental angiogen-
esis during late gestation in pregnant ewes. The toco-
pherol concentrations of uterus and placentome
increased following oral supplementation. In aT supple-
mented ewes, mRNA expression of PlGF, eNOS and
HIF-1a in cotyledon were greater than the CON group.
In gT supplemented ewes, VEGF and eNOS mRNA
expressions in caruncle and uterus, and HIF-1a in coty-
ledon, HIF-1a and HIF-2 a in caruncle and uterus were
greater than the CON group. Morphometry analysis
revealed angiogenic parameters favoring increased
angiogenesis. Given the findings, it is plausible that the
angiogenesis observed in this study might be a prooxi-
dant and proangiogenesis pathway. Based on the results
observed in this study we confer that the tocopherols
supplementation can be employed to promote placental
angiogenesis during late gestation. The oral tocopherol
supplementation may be considered as an option to
overcome pregnancy complications due to placental
ischemia during late gestation.
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